August 29, 2019 - New Device Approved to Treat the Prostate – and more news

August 29, 2019
New Ultrasound Device to Treat the Prostate Receives FDA Approval

Profound Medical recently announced that its TULSA-PRO® device has earned 510(k) clearance by the US Food and Drug Administration (FDA) to ablate prostate tissue. This is the first transurethral ultrasound device approved in the US, and it allows physicians to predictably ablate whole-gland or partial prostate tissue.

 Foundation News
Workshop Held to Explore Advanced Imaging for Targeting the Brain in Focused Ultrasound Procedures

The Foundation recently hosted a workshop to discuss the potential value of adding tractography as a targeting tool for transcranial focused ultrasound treatments. 


Eight Summer Interns Assist in a Variety of Projects

This summer, student interns completed a number of projects in various Foundation departments. 


Blog Addresses the Benefits of Integrated Comparative Clinical Trials

The traditional path to bring new therapies from the laboratory bench to the patients' bedside is relatively straight, but why isn't it more successful?


Research News
Novel Approach for Treating the Brain Awarded $2.4 Million Research Grant

University of Michigan researchers were awarded a four-year, $2.4M grant from the National Institute of Biomedical Imaging and Bioengineering to study transcranial histotripsy.


Meeting Report: B3DD Summit

The inaugural B3DD Summit addressed challenges for effective and safe drug delivery of central nervous system agents across the blood-brain barrier.


Research Roundup

Nathan McDannold, PhD, and team found temporary but notable functional MRI changes in rats undergoing focused ultrasound—based blood-brain barrier opening.

Visit our free, online research library of focused ultrasound publications.
 More Research News
Industry News
The Gap between Regulatory Approval and Reimbursement Discussed in Op-Ed

Mark Carol, CEO of SonaCare Medical, writes about the challenges for medical device companies that have regulatory approval as they await Medicare coverage for their treatments. 


Reimbursement Presentation Explains Correct Billing Practices

The Foundation has posted a brief presentation about its Reimbursement Seminars to help treatment sites ensure that they are billing correctly for focused ultrasound procedures.


Do you have news for our newsletter? Tell us about it! 
Upcoming Events
August 29-31, 2019 5th World Congress on Parkinsons & Huntington Disease, Vienna, Austria 

September 5, 2019 Medical Device Innovation Consortium (MDIC) Annual Public Forum, Washington, DC

September 12-14, 2019 4th International Symposium on Hypothalamic Hamartomas, Washington, DC

September 15-18, 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, Chicago, IL

September 16-17, 2019 20th International Conference on Alzheimer's Drug Discovery, Jersey City, NJ

September 22-26, 2019 International Congress of Parkinson's Disease and Movement Disorders, Nice, France

September 23-24, 2019 Focused Ultrasound Neuromodulation Symposium, Oxford, UK  
Poster Deadline is September 2, 2019

September 27 – October 1, 2019 European Society for Medical Oncology Congress, Barcelona, Spain

October 6-9, 2019 IUS IEEE International Ultrasonics Symposium, Glasgow, Scotland

October 10-11, 2019 31st International Congress of the Society for Medical Innovation and Technology (SMIT), Heilbronn, Germany

October 13-15, 2019 American Neurological Association (ANA) Annual Meeting, St. Louis, MO

October 15, 2019 The Michael J. Fox Foundation 13th Annual Parkinson's Disease Therapeutics Conference, New York, NY

October 28-30, 2019 Milken Institute - Future of Health Summit, Washington, DC